{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-3003"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-3003","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Dexmedetomidine adjunctive ketamine to enhance attenuation of methamphetamine-induced agitation","abstract":"Agitation caused by methamphetamine (METH) use is a common and serious issue in emergency settings. While sedatives like benzodiazepines are often used, they can be dangerous, especially when breathing is already compromised due to METH-opioid co-exposure. Dexmedetomidine (DEXMED) is a safer alternative that provides sedation without major effects on breathing, but it can lower heart rate and blood pressure when used at high doses. This thesis project focused on finding whether combining low-dose DEXMED with ketamine (KET) can safely and effectively manage METH-induced agitation in a rat model. Using METH to trigger hyperactivity, we will test whether this combination could reduce agitation and offer better sedation than DEXMED alone while possibly yielding a more so ideal side effect profile than that of higher DEXMED doses.","abstract_html":"Agitation caused by methamphetamine (METH) use is a common and serious issue in emergency settings. While sedatives like benzodiazepines are often used, they can be dangerous, especially when breathing is already compromised due to METH-opioid co-exposure. Dexmedetomidine (DEXMED) is a safer alternative that provides sedation without major effects on breathing, but it can lower heart rate and blood pressure when used at high doses. This thesis project focused on finding whether combining low-dose DEXMED with ketamine (KET) can safely and effectively manage METH-induced agitation in a rat model. Using METH to trigger hyperactivity, we will test whether this combination could reduce agitation and offer better sedation than DEXMED alone while possibly yielding a more so ideal side effect profile than that of higher DEXMED doses.","abstract_has_math":false,"creators":["Budamkayala, Madhuri"],"institution":null,"degree_name":"Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"School of Pharmacy","degree_department":null,"school":null,"contributors":["Dr. Michael Hambuchen","Dr. Cynthia B Jones","Dr. Eric Blough"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:58:17Z","subjects":["Medicine and Health Sciences","Other Pharmacy and Pharmaceutical Sciences","Pharmacy and Pharmaceutical Sciences","Dexmedetomidine (DEXMED)","methamphetamine (METH)","ketamine (KET)","METH-induced agitation","sedation"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/1998","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/1998","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-3003","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Michael Hambuchen","Dr. Cynthia B Jones","Dr. Eric Blough"]},{"key":"dc:creator","label":"Author","values":["Budamkayala, Madhuri"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-11-17T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2025-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["School of Pharmacy"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicine and Health Sciences","Other Pharmacy and Pharmaceutical Sciences","Pharmacy and Pharmaceutical Sciences","Dexmedetomidine (DEXMED)","methamphetamine (METH)","ketamine (KET)","METH-induced agitation","sedation"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/1998"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Agitation caused by methamphetamine (METH) use is a common and serious issue in emergency settings. While sedatives like benzodiazepines are often used, they can be dangerous, especially when breathing is already compromised due to METH-opioid co-exposure. Dexmedetomidine (DEXMED) is a safer alternative that provides sedation without major effects on breathing, but it can lower heart rate and blood pressure when used at high doses. This thesis project focused on finding whether combining low-dose DEXMED with ketamine (KET) can safely and effectively manage METH-induced agitation in a rat model. Using METH to trigger hyperactivity, we will test whether this combination could reduce agitation and offer better sedation than DEXMED alone while possibly yielding a more so ideal side effect profile than that of higher DEXMED doses."]},{"key":"dc:title","label":"Title","values":["Dexmedetomidine adjunctive ketamine to enhance attenuation of methamphetamine-induced agitation"]}]}],"canonical_facts":{"dc:contributor":["Dr. Michael Hambuchen","Dr. Cynthia B Jones","Dr. Eric Blough"],"dc:creator":["Budamkayala, Madhuri"],"dc:date.available":["2026-11-17T08:00:00Z"],"dc:date.created":["2025-01-01T08:00:00Z"],"dc:description.abstract":["Agitation caused by methamphetamine (METH) use is a common and serious issue in emergency settings. While sedatives like benzodiazepines are often used, they can be dangerous, especially when breathing is already compromised due to METH-opioid co-exposure. Dexmedetomidine (DEXMED) is a safer alternative that provides sedation without major effects on breathing, but it can lower heart rate and blood pressure when used at high doses. This thesis project focused on finding whether combining low-dose DEXMED with ketamine (KET) can safely and effectively manage METH-induced agitation in a rat model. Using METH to trigger hyperactivity, we will test whether this combination could reduce agitation and offer better sedation than DEXMED alone while possibly yielding a more so ideal side effect profile than that of higher DEXMED doses."],"dc:identifier":["https://mds.marshall.edu/etd/1998"],"dc:subject":["Medicine and Health Sciences","Other Pharmacy and Pharmaceutical Sciences","Pharmacy and Pharmaceutical Sciences","Dexmedetomidine (DEXMED)","methamphetamine (METH)","ketamine (KET)","METH-induced agitation","sedation"],"dc:title":["Dexmedetomidine adjunctive ketamine to enhance attenuation of methamphetamine-induced agitation"],"thesis:degree_discipline":["School of Pharmacy"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Pharmaceutical Sciences"]},"updated_at":"2026-11-21T19:58:17Z"}